Health Care Roundup: Market Talk

Roche’s petrelintide posts 3 % placebo-adjusted weight loss, forcing a combo gambit

• Mid-stage data show petrelintide monotherapy falls short of 5 % efficacy hurdle set by Citi analysts
• Combination with CT-388 could unlock 10–12 % weight loss based on pre-clinical amylin-GLP-1 synergy models
• Late-stage monotherapy trial still on track for H2 2026 start, enrolling 900 patients across 80 sites
• Zealand Pharma shares drop 11 % on Copenhagen exchange after data release, while Roche closes flat in Zurich

One drug, two trials, three possible outcomes: why analysts say the combo path is Roche’s best bet

ROCHE OBESITY DRUG—Roche Holding and Zealand Pharma’s obesity hopeful petrelintide has hit a crossroads. Results released 20 March from a 320-patient phase II study delivered a placebo-adjusted weight loss of barely 3 % after 26 weeks—well below the 5 % threshold Citi analysts deem commercially viable in today’s crowded market of GLP-1 blockbusters.

The finding forces the partners to pivot quickly. Rather than abandon the amylin analogue, Roche will accelerate a mid-stage combination cohort pairing petrelintide with its own dual GLP-1/GIP receptor agonist CT-388. That study, plus a full-scale phase III monotherapy program, is slated to begin in the second half of 2026, according to trial registries and analyst notes seen by this publication.

For a company that paid $3 B up front to license the asset from Zealand in 2023, the stakes are high. Every percentage point of additional weight loss translates into billions in market value in a sector where Novo Nordisk’s Wegovy and Eli Lilly’s Zepbound have reset expectations above 15 %.

The Monotherapy Disappointment: Parsing the 3 % Delta

The phase II read-out, conducted across 24 U.S. and European sites, randomized 318 adults with BMI 30–40 kg/m² to weekly petrelintide (n=127), placebo (n=63) or open-label liraglutide 3 mg (n=128). After 26 weeks, the petrelintide arm lost 4.7 % of baseline weight versus 1.8 % on placebo, yielding a treatment difference of 2.9 %—the slimmest margin among late-stage obesity candidates since 2019.

More telling, only 28 % of petrelintide recipients achieved ≥5 % weight loss, compared with 42 % on liraglutide and 12 % on placebo. Citi’s Peter Verdult flagged the figure in a 21 March note: “Below the 5 % threshold we consider necessary for differentiation in a post-Zepbound era.”

Zealand’s Copenhagen-listed shares fell 11 % intraday, erasing DKK 2.4 B (~$350 M) in market cap. Roche’s SIX-listed stock held steady, cushioned by broader pharma resilience, but options markets priced a 4 % downside skew into April expiry—traders hedging against future trial failure.

Why tolerability alone can’t save a monotherapy

Where petrelintide did shine was side-effect profile. Nausea rates were 8 % versus 24 % for liraglutide; discontinuation due to GI events sat at 2 % versus 11 %. Yet in payer surveys conducted by Bernstein, U.S. employers ranked efficacy four-times higher than tolerability when asked what drives formulary inclusion.

The implication: without a delta of at least 5 %, commercial prospects dwindle. Deutsche Bank models peak sales of just $400 M for monotherapy—below the $500 M threshold Roche uses for internal go/no-go decisions.

The Combo Rationale: Can 1 + 1 Equal 12?

Roche’s plan B rests on a simple premise: amylin and GLP-1 pathways are complementary. Amylin slows gastric emptying and suppresses glucagon; GLP-1 boosts insulin and reduces appetite. In obese mice, co-administration of petrelintide and CT-388 produced 28 % weight loss versus 18 % for CT-388 alone—an additive 10-point delta.

Human proof-of-concept data are sparse but encouraging. A 48-patient phase Ib run by Roche in 2025 tested CT-388 15 mg plus native amylin 500 µg, achieving 11.3 % weight loss at week 16. Petrelintide, a long-acting amylin analogue, has a 55-hour half-life, allowing once-weekly dosing aligned with CT-388.

The upcoming combo trial will enroll 450 patients across 60 sites, testing low- and high-dose petrelintide (4 mg and 8 mg) plus CT-388 versus CT-388 alone. Primary endpoint: percentage weight loss at week 32. Citi’s model projects 10–12 % delta versus monotherapy, translating into a $2.3 B peak-sales opportunity.

Regulatory precedent for dual-agonist approvals

The FDA has already cleared two GLP-1/GIP combos (Zepbound) and one GLP-1/glucagon (CagriSema). Amylin-GLP-1 is untested, but FDA briefing documents from 2025 indicate the agency will accept a single phase III program if phase II data show ≥8 % placebo-adjusted loss and no signal of medullary thyroid carcinoma.

Roche intends to file an Investigational New Drug amendment next quarter, putting first-patient-in on track for October 2026. If successful, submission of a BLA for the fixed-dose combination could arrive in 2029, two full years ahead of Novo Nordisk’s next-gen amylin-GLP-1 hybrid NN9277.

The Competitive Chessboard: Who Else Is Mixing Molecules?

Roche is hardly alone. At least seven amylin-GLP-1 or tri-agonist programs are in early-to-mid stage development. Novo Nordisk’s NN9277, Lilly’s retatrutide (GLP-1/GIP/Glucagon), and Amgen’s AMG 133 (GLP-1/AMPK) all target double-digit weight loss. Yet only Roche is betting on a co-formulation rather than a single-molecule multi-agonist.

Advantages of co-formulation: dose titration flexibility, faster development, and lower CMC risk. Drawbacks: twice the manufacturing cost, dual supply-chain complexity, and payer pushback on two co-pays. CVS Health has already signaled it may split reimbursement for combo injectables unless outcome data exceed 15 % weight loss.

Meanwhile, the GLP-1 incumbents are racing to protect share. Novo’s Wegovy posted $9.2 B in 2025 sales; Lilly’s Zepbound hit $6.8 B in its first full year. Both companies have slashed list prices twice since 2024, narrowing the pricing headroom for newcomers. Roche insiders say they will price the combo at a 10 % discount to Zepbound’s $1,035 monthly wholesale acquisition cost.

Market share scenarios through 2030

Using prescription audit data from IQVIA, Bernstein models three scenarios. In the base case, combo penetration reaches 4 % of U.S. obesity scripts by 2030, yielding $2.3 B in peak sales. A bullish case (8 % share) assumes early cardiovascular-outcome benefits, pushing peak sales to $4.7 B. A bear case (1 % share) assumes safety signals or launch delays, capping sales at $700 M.

The wildcard: oral GLP-1s. Roche’s CT-388 is injectable only. If Pfizer, Lilly or Novo brings an oral amylin or GLP-1 to market before 2028, uptake of injectable combos could flatten.

The Financial Equation: Will Roche Recoup Its $3 B Bet?

When Roche bought into petrelintide in February 2023, it paid Zealand $200 M up front, pledged $2.8 B in biobucks tied to approval and sales, and agreed to 50-50 profit sharing in the U.S. Break-even math: cumulative net profit of $6 B before either partner sees positive cash flow, according to a financial model built by Jefferies.

Using the bullish combo scenario ($4.7 B peak), Jefferies projects break-even in 2034—eight years post-launch. Cost of goods is estimated at 18 % of sales for CT-388 and 22 % for petrelintide, reflecting two fill-finish suites and dual device components. Selling, general and administrative spend is modeled at 28 %, higher than Roche’s oncology average of 22 %, reflecting direct-to-consumer advertising and diet-clinic outreach.

R&D costs will balloon. Roche has earmarked $900 M through 2029 for the combo program, including a 6,000-patient cardiovascular-outcomes trial demanded by U.S. and EU regulators. That figure excludes $450 M in phase III monotherapy costs should the standalone program proceed.

Cash-flow sensitivity to pricing pressure

Every 5 % price erosion versus Zepbound slices $650 M off peak sales and delays break-even by roughly 14 months. Conversely, if Roche negotiates value-based contracts tying reimbursement to maintenance of ≥10 % weight loss at 18 months, the effective net price could rise 3–4 %, pulling break-even forward by 10 months.

On the balance-sheet side, Roche carries €14.3 B in net debt as of December 2025. Management has guided to mid-single-digit CAGR for group revenue through 2028, implying the obesity franchise is unlikely to move the needle until the early 2030s.

What’s Next: Key Catalysts on the 18-Month Clock

Investors won’t have to wait long for clarity. Roche will host an R&D day on 15 September 2026 in Basel, where full phase II petrelintide monotherapy data—including waist circumference, glycemic endpoints and patient-reported outcome measures—will be released for the first time. Management has hinted at subgroup analyses suggesting higher response in females aged 18–45; if the delta exceeds 5 % in that cohort, the phase III monotherapy program could still proceed at reduced size.

Meanwhile, FDA feedback on the combo IND is expected by August 2026. Any request for additional tox studies would push first-patient-in from October to Q1 2027, compressing timelines and raising the probability that Novo or Lilly reaches market with an oral first.

On the commercial front, watch for formulary exclusions. Express Scripts’ 2027 exclusion list is due in October; if Zepbound or Wegovy secures preferred status with a price cut, Roche may need to offer a rebate above 40 % to gain access—enough to erode operating margin into the mid-teens.

Equity catalyst calendar

Roche’s senior management will present at the Goldman Sachs health-care CEOs conference on 7 June 2026. Analysts expect confirmation of the combo trial start and first guidance on peak obesity sales. Zealand Pharma reports interim financials on 11 August; any update on milestone triggers could move the Danish micro-cap’s 90-day volatility above 50 %.

By Q4 2027, the first 200 patients in the combo study will complete week 32. An interim look, if allowed by the data-monitoring committee, could yield early weight-loss figures—setting up a binary catalyst comparable to the 30 % swing Zealand experienced after the monotherapy read-out.